Liver Vessel Enhancement by Gd-BOPTA and Gd-EOB-DTPA: A Comparison in Healthy Volunteers

被引:75
作者
Brismar, T. B. [1 ]
Dahlstrom, N. [2 ,3 ]
Edsborg, N.
Persson, A. [3 ]
Smedby, O. [3 ,4 ]
Albiin, N.
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Radiol, SE-14186 Stockholm, Sweden
[2] Hudiksvall Hosp, Dept Radiol, Hudiksvall, Sweden
[3] Linkoping Univ, Ctr Med Image Sci & Visualizat, Linkoping, Sweden
[4] Linkoping Univ, Dept Radiol IMH, Linkoping, Sweden
关键词
Contrast dynamics; Gd-BOPTA; Gd-EOB-DTPA; liver; MRI; GADOBENATE DIMEGLUMINE; CLINICAL-EVALUATION; CONTRAST AGENTS; PHARMACOKINETICS; SAFETY; MRI;
D O I
10.1080/02841850903055603
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: A thorough understanding of magnetic resonance (MR) contrast media dynamics makes it possible to choose the optimal contrast media for each investigation. Differences in visualizing hepatobiliary function between Gd-BOPTA and Gd-EOB-DTPA have previously been demonstrated, but less has been published regarding differences in liver vessel visualization. Purpose: To compare the liver vessel and liver parenchymal enhancement dynamics of Gd-BOPTA (MultiHance) and Gd-EOB-DTPA (Primovist). Material and Methods: The signal intensity of the liver parenchyma, the common hepatic artery, the middle hepatic vein, and a segmental branch of the right portal vein was obtained in 10 healthy volunteers before contrast media administration, during arterial and portal venous phases, and 10, 20, 30, 40, and 130 min after intravenous contrast medium injection, but, due to scanner limitations, not during the hepatic venous phase. The doses of contrast media were 0.1 mmol/kg for Gd-BOPTA and 0.025 mmol/kg for Gd-EOB-DTPA. Results: Maximum enhancement of liver parenchyma was observed from the portal venous phase until 130 min after Gd-BOPTA administration and from 10 min to 40 min after Gd-EOB-DTPA. There was no difference in maximum enhancement of liver parenchyma between the two contrast media. When using Gd-BOPTA, the vascular contrast enhancement was still apparent 40 min after injection, but had vanished 10 min after Gd-EOB-DTPA injection. The maximum difference in signal intensity between the vessels and the liver parenchyma was significantly greater with Gd-BOPTA than with Gd-EOB-DTPA (P<0.0001). Conclusion: At the dosage used in this study, Gd-BOPTA yields higher maximum enhancement of the hepatic artery, portal vein, and middle hepatic vein during the arterial and the portal venous phase and during the delayed phases than Gd-EOB-DTPA does, whereas there is no difference in liver parenchymal enhancement between the two contrast agents.
引用
收藏
页码:709 / 715
页数:7
相关论文
共 17 条
  • [1] [Anonymous], FDA INF HEALTHC PROF
  • [2] Biliary Imaging with Gd-EOB-DTPA: Is a 20-minute delay sufficient?'
    Carlos, RC
    Branam, JD
    Dong, Q
    Hussain, HK
    Francis, IR
    [J]. ACADEMIC RADIOLOGY, 2002, 9 (11) : 1322 - 1325
  • [3] Hepatocellular carcinoma in liver transplantation candidates: Detection with gadobenate dimeglumine-enhanced MRI
    Choi, Seung Hong
    Lee, Jeong Min
    Yu, Nam C.
    Suh, Kyung-Suk
    Jang, Ja-June
    Kim, Se Hyung
    Choi, Byung Ihn
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 191 (02) : 529 - 536
  • [4] Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects
    Dahlstrom, N.
    Persson, A.
    Albiin, N.
    Smedby, O.
    Brismar, T. B.
    [J]. ACTA RADIOLOGICA, 2007, 48 (04) : 362 - 368
  • [5] Magnetic resonance angiography with blood-pool contrast agents: future applications
    Fink, Christian
    Goyen, Mathias
    Lotz, Joachim
    [J]. EUROPEAN RADIOLOGY, 2007, 17 : B38 - B44
  • [6] Modern imaging for liver metastases from colorectal tumors
    Gaa J.
    Wieder H.
    Schwaiger M.
    Rummeny E.J.
    [J]. Der Chirurg, 2005, 76 (6): : 525 - 534
  • [7] Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: Prospective study
    Grazioli, L
    Morana, G
    Kirchin, MA
    Schneider, G
    [J]. RADIOLOGY, 2005, 236 (01) : 166 - 177
  • [8] PHASE-I CLINICAL-EVALUATION OF GD-EOB-DTPA AS A HEPATOBILIARY MR CONTRAST AGENT - SAFETY, PHARMACOKINETICS, AND MR-IMAGING
    HAMM, B
    STAKS, T
    MUHLER, A
    BOLLOW, M
    TAUPITZ, M
    FRENZEL, T
    WOLF, KJ
    WEINMANN, HJ
    LANGE, L
    [J]. RADIOLOGY, 1995, 195 (03) : 785 - 792
  • [9] Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma
    Kim, YK
    Kim, CS
    Chung, GH
    Han, YM
    Lee, SY
    Bin Chon, S
    Lee, JM
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (01) : 149 - 157
  • [10] Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions
    Kim, YK
    Lee, JM
    Kim, CS
    [J]. EUROPEAN RADIOLOGY, 2004, 14 (01) : 5 - 13